KR20180026021A - Method of Manufacturing Kombucha with Extracts Using Green Tea and Citrus - Google Patents
Method of Manufacturing Kombucha with Extracts Using Green Tea and Citrus Download PDFInfo
- Publication number
- KR20180026021A KR20180026021A KR1020160112720A KR20160112720A KR20180026021A KR 20180026021 A KR20180026021 A KR 20180026021A KR 1020160112720 A KR1020160112720 A KR 1020160112720A KR 20160112720 A KR20160112720 A KR 20160112720A KR 20180026021 A KR20180026021 A KR 20180026021A
- Authority
- KR
- South Korea
- Prior art keywords
- green tea
- extract
- citrus
- comb
- kombucha
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 38
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 13
- 235000020971 citrus fruits Nutrition 0.000 title claims description 42
- 241000207199 Citrus Species 0.000 title claims description 36
- 235000019226 kombucha tea Nutrition 0.000 title abstract description 18
- 244000269722 Thea sinensis Species 0.000 claims abstract description 39
- 235000009569 green tea Nutrition 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 17
- 238000002156 mixing Methods 0.000 claims abstract description 15
- 238000012258 culturing Methods 0.000 claims abstract description 10
- 239000001963 growth medium Substances 0.000 claims abstract description 10
- 235000006468 Thea sinensis Nutrition 0.000 claims abstract description 7
- 235000020279 black tea Nutrition 0.000 claims abstract description 7
- 235000020688 green tea extract Nutrition 0.000 claims description 33
- 229940094952 green tea extract Drugs 0.000 claims description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000012153 distilled water Substances 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 239000012228 culture supernatant Substances 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 abstract description 24
- 230000003078 antioxidant effect Effects 0.000 abstract description 18
- 239000000203 mixture Substances 0.000 abstract description 11
- 239000003963 antioxidant agent Substances 0.000 abstract description 4
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 230000000845 anti-microbial effect Effects 0.000 abstract description 3
- 238000000605 extraction Methods 0.000 abstract description 3
- 230000003908 liver function Effects 0.000 abstract description 2
- 229910052760 oxygen Inorganic materials 0.000 abstract description 2
- 239000001301 oxygen Substances 0.000 abstract description 2
- 240000002319 Citrus sinensis Species 0.000 abstract 4
- 235000005976 Citrus sinensis Nutrition 0.000 abstract 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 37
- 206010005003 Bladder cancer Diseases 0.000 description 13
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 13
- 201000005112 urinary bladder cancer Diseases 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 235000013616 tea Nutrition 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 231100000002 MTT assay Toxicity 0.000 description 5
- 238000000134 MTT assay Methods 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 235000019614 sour taste Nutrition 0.000 description 5
- 208000000453 Skin Neoplasms Diseases 0.000 description 4
- 201000000849 skin cancer Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 235000019985 fermented beverage Nutrition 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 244000126211 Hericium coralloides Species 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- JMFSHKGXVSAJFY-UHFFFAOYSA-N Saponaretin Natural products OCC(O)C1OC(Oc2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C1O JMFSHKGXVSAJFY-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- MOZJVOCOKZLBQB-UHFFFAOYSA-N Vitexin Natural products OCC1OC(Oc2c(O)c(O)cc3C(=O)C=C(Oc23)c4ccc(O)cc4)C(O)C(O)C1O MOZJVOCOKZLBQB-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- SGEWCQFRYRRZDC-VPRICQMDSA-N vitexin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O SGEWCQFRYRRZDC-VPRICQMDSA-N 0.000 description 1
- PZKISQRTNNHUGF-UHFFFAOYSA-N vitexine Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=CC(O)=CC=1)=CC2=O PZKISQRTNNHUGF-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
- A23F3/08—Oxidation; Fermentation
- A23F3/10—Fermentation with addition of microorganisms or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F2200/00—Special features
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/38—Multiple-step
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 감귤 및 녹차 추출액을 이용한 콤부차 제조방법 에 관한 것으로, 보다 상세하게는 활성산소의 생성억제를 통한 항산화력, 항균성, 항암성, 간기능 보호 등의 효능을 가지는 감귤 및 녹차 추출액을 이용한 콤부차 제조방법 에 관한 것이다.
More particularly, the present invention relates to a method for producing combat tea using citrus fruits and green tea extracts, and more particularly, to a method for producing combat tea using citrus fruits and green tea extracts having an antioxidant ability, antimicrobial activity, anticancer activity, The present invention relates to a method for manufacturing a comb secondary structure.
콤부차는 국내에서는 홍차버섯으로 알려진 박테리아와 효모의 공생균사체에 의해 발효되어 얻어지는 발효 음료로 주로 홍차와 설탕을 주원료로 한다. 콤부차는 고대 중국의 진 나라로부터 기원되었으며 해독작용과 강장효과가 높아 “신성한 차”로 불렸다고 하며, 이후 서기 414년경에 한국을 거쳐 일본으로 전해졌으며 현재는 주로 러시아 지역을 중심으로 “Tea Kvass"라는 이름으로 불리며 많이 음용되고 있다(1). 콤부차의 생리활성 및 공공 보건에 미치는 영향과 관련하여 많은 연구가 진행되고 있으며, 대표적으로 활성산소 생성억제를 통한 항산화력(2), 항균성(3), 항암성(4), 상처치료 효과(5), 간기능 보호(6-8) 등의 다양한 생리활성이 보고되어 있다. 이 중 콤부차의 항암활성에 대한 연구를 살펴 보면, Jayabalan 등(9)은 콤부차 추출물의 여러 용매 분획물에 대한 항암 활성을 측정한 결과 ethyl acetate 분획물에서 강력한 항암 활성을 관찰하였고, 물질의 정제 및 분리를 통하여, 말론산과 vitexin이 유효 성분임을 밝혀낸 바 있다. Srihari 등(4)은 인체 전립선암인 PC-3를 이용하여 콤부차의 항암활성을 측정하였는데 표적 분자들 중 특히 interleukin8과 VEGF의 m-RNA 발현이 현저히 감소함을 확인한 바 있으며, in vivo 신생 혈관 생성에 관여하는 것으로 알려진 matrix metalloproteinases-2 와 -9의 활성이 크게 저하됨을 확인하였다. Kombucha is a fermented beverage which is fermented by the symbiotic mycelium of bacteria and yeast, known as black tea mushroom in Korea, and mainly made of black tea and sugar. Kombucha originated from ancient China and was said to have been called a "sacred tea" because of its detoxification and tonic effects. It was passed to Korea through Korea in about AD 414, and now mainly in Russia. "Tea Kvass (2), antimicrobial activity (2), antioxidant activity (2), and antioxidant activity (2). In addition, 3), anticancer effects (4), wound healing effects (5), liver function protection (6-8), etc. Jaeabalan et al. (9) measured the anticancer activity of several fractions of Combaucha extract and found strong anticancer activity in the ethyl acetate fraction. Through the purification and separation of substances, malonic acid and vitexin were found to be effective components . Srihari et al. (4) measured the anticancer activity of combat tumor using PC-3, a human prostate cancer, and found that m-RNA expression of interleukin8 and VEGF, especially of target molecules, was significantly reduced , and the activity of matrix metalloproteinases-2 and -9, which are known to be involved in the formation of neovascularization in vivo, is greatly reduced.
그러나, 콤부차의 다양한 생리활성에도 불구하고, 산업계에서의 응용 및 활용도는 현저하게 낮은데, 그 주된 원인으로는 콤부차의 발효가 미생물의 공생체를 통해 이루어지므로 사용되는 미생물의 정확한 균종 및 분포가 확립되지 않아 발생하는 미생물 안전성 및 발효 산물의 정상 세포에 대한 독성 여부를 들 수 있다. 특히 콤부차의 세포 독성에 관한 연구 결과는 일치되지 않으며, 많은 논란이 있다. 한 예로 미국의 Centers for Disease Control and Prevention(CDC)는 1995년 미국의 Iowa 주에서 콤부차 음용으로부터 발생한 2건의 임상 사례를 보고한 바 있는데, 정확한 원인은 파악이 되지 않았으나, 콤부차의 낮은 산도에 따른 세포 독성의 가능성을 제시한 바 있고(10), Srinivasan 등(11)은 콤부차를 음용한 후 발생한 환자 4명의 임상 사례를 통하여, 콤부차의 독성 가능성을 제시하였으나, 이 연구에서도 그의 직접적인 원인은 밝혀지지 않았다. 또 다른 연구들에서는 콤부차의 세포 독성이 없음을 보고하였는데, Bhattacharya 등(12)은 실험용 쥐를 이용한 실험에서 kg당 2 mL 혹은 증류수에 1%(v/v)를 첨가한 콤부차를 3개월 동안 먹인 후 장기 독성, 체중 등을 조사한 결과 독성이 없음을 보고한 바 있다. 미국 FDA에서도 콤부차가 GMP(Good Manufacturer's Practice) 과정을 거쳐 생산되면, 소비자가 섭취하기에 적합하며, 독성이 없다고 확인한 바 있으며(13), 기존에 보고된 세포 독성들도 높은 산도, 과량의 섭취, 비위생적 생산 등과 관련되었을 수 있다고 보고하였다. However, in spite of various physiological activities of kombucha, the application and utilization in industry are remarkably low. The main cause is the fermentation of kombucha through microbial symbiosis, so that the exact species and distribution of microorganisms used are established And the toxicity of the fermentation products to normal cells. In particular, the results of studies on the cytotoxicity of combusca are not consistent, and there is a lot of controversy. For example, Centers for Disease Control and Prevention (CDC) in the United States reported two clinical cases in 1995 in the state of Iowa, (10), Srinivasan et al. (11) suggested the possibility of toxicity in combatua through clinical cases of four patients who ingested combat, but in this study, Was not revealed. In another study, Bhattacharya et al. (12) reported that in a laboratory experiment, 2 ml per kg, or 1% (v / v) of distilled water, . In the present study, we found that the toxicity was not observed as a result of long-term toxicity and weight. The US FDA has also confirmed that Comvouta is produced by the Good Manufacturer's Practice (GMP) process and is suitable for consumer intake and is not toxic (13). Previously reported cytotoxic effects also include high acidity, excessive intake , And unsanitary production.
대한민국 공개특허 제2015-0124258호에서는 콤부차 발효 조성물에 관하여 개시하고 있다. 이 발명에서는 녹차액, 배양액 및 한약재 추출물을 함유하여 항암효과를 가지는 조성물을 기재하고 있지만, 콤부차의 맛에 한약재의 맛이 더해저 음용하기 어렵다는 단점을 가진다.Korean Patent Laid-Open Publication No. 2015-0124258 discloses a combing tea fermentation composition. Although the present invention describes a composition having an anticancer effect by containing a green tea liquid, a culture liquid and a herbal medicine extract, it has a disadvantage in that it tends to be difficult to drink the flavor of herbal medicines even in the taste of combat tea.
대한민국등록특허 제0482308호에서는 녹차이용 콤부차음료의 제조방법에 관하여 개시하고 있다. 이 발명에서는 홍차 추출액에 녹차 추출물, 당을 혼합한 다음, 발효하여 제조되는 콤부차 발효음료를 기재하고 있지만, 기존의 콤부차 이상의 효능을 기대하기 어렵다는 단점을 가진다.
Korean Patent Registration No. 0482308 discloses a method for producing a combus tea drink using green tea. The present invention describes a comb-secondary fermented beverage which is prepared by mixing a green tea extract and a sugar in a black tea extract and then fermenting it, but it has a disadvantage that it is difficult to expect an efficacy higher than that of a conventional comb supplement.
발명은 상기 문제점을 해결하고자 안출된 것으로, 기존의 콤부차에 녹차 및 감귤 추출물을 혼합하여, 음용하기 쉬우며 항암효과 및 항산화효과가 개선된 감귤 및 녹차 추출액을 이용한 콤부차 제조방법 을 제공하고자 한다.
DISCLOSURE OF THE INVENTION An object of the present invention is to provide a method for manufacturing a comb secondary carcass using citrus fruits and green tea extracts, which are easy to drink, and have improved anticancer and antioxidant effects, by mixing green tea and citrus fruit extracts with existing combuecha .
상기 과제를 해결하기 위하여 본 발명은, (a) 콤부차 균주를 홍차와 혼합한 다음 1차 배양하여 콤부차 배양액을 수득한 다음, 배양액과 세균막(Pellicle)을 분리하는 단계; (b) 녹차 추출액 및 감귤 추출액을 준비하는 단계; 및 (c) 상기 콤부차 배양액, 새균막, 녹차 추출액 및 감귤 추출액을 혼합한 다음, 2차 배양하여 콤부차를 수득하는 단계를 포함하는 감귤 및 녹차 추출액을 이용한 콤부차 제조방법을 제공한다.In order to solve the above-mentioned problems, the present invention provides a method for culturing a microorganism, comprising: (a) mixing a microbial strain with a black tea, followed by primary culture to obtain a comb culture medium, and then separating the culture medium and a pellicle; (b) preparing green tea extract and citrus extract; And (c) a step of mixing the comb culture medium, fresh culture medium, green tea extract and citrus extract, and then culturing the mixture to obtain comb seeds, thereby producing comb seeds using citrus fruits and green tea extracts.
또한 상기 녹차 추출액은 설탕을 추가로 포함하는 것을 특징으로 하는 콤부차 제조방법을 제공한다.Also, the green tea extract may further comprise sugar.
또한 상기 콤부차 추출액은 아세트산을 추가로 포함하는 것을 특징으로 하는 콤부차 제조방법을 제공한다.Also, the comb secondary extract preferably further comprises acetic acid.
또한 상기 녹차 추출액은 녹차 1~5g을 100~500mL의 증류수에 90~120℃의 온도로 1~30분간 추출한 것을 특징으로 하는 콤부차 제조방법을 제공한다.Also, the green tea extract is prepared by extracting 1 to 5 g of green tea with 100 to 500 ml of distilled water at a temperature of 90 to 120 ° C for 1 to 30 minutes.
또한 상기 감귤 추출액은 감귤피 1~30g을 100~500mL의 증류수에 90~120℃의 온도로 1~30분간 추출한 것을 특징으로 하는 콤부차 제조방법을 제공한다.Also, the citrus extract may be prepared by extracting 1 to 30 g of citrus peel from 100 to 500 mL of distilled water at a temperature of 90 to 120 ° C for 1 to 30 minutes.
또한 상기 (c)단계는 콤부차 배양액 50~200mL, 세균막 1-~50g, 녹차 추출액 500~1200mL 및 감귤 추출액 100~300mL를 혼합하여 10~40℃에서 5~20일간 배양하는 것을 특징으로 하는 콤부차 제조방법을 제공한다.(C) is performed by mixing 50 to 200 mL of a comb culture medium, 1- to 50 g of a bacterial membrane, 500 to 1200 mL of an green tea extract, and 100 to 300 mL of a citrus extract, and culturing the mixture at 10 to 40 ° C. for 5 to 20 days. To provide a secondary manufacturing method.
또한 제1항 내지 제6항 중 어느 한 가지 방법으로 제조되는 콤부차를 제공한다.
A comb secondary car produced by the method of any one of claims 1 to 6 is also provided.
이러한 본 발명에 따르면, 기존의 콤부차에 항산화활성을 높이기 위하여 녹차 및 감귤 추출액을 혼합함에 따라, 높은 항산화 활성을 가지고, 항암성능 역시 뛰어나며, 감귤 추출액의 혼합으로 인하여 음용하기 역시 쉬우므로, 건강음료, 건강보조식품 등의 제조에 유용하다.
According to the present invention, by mixing the green tea and the citrus extract to enhance the antioxidative activity of the existing comb tooth, it has a high antioxidative activity and excellent anticancer performance, and because it is easy to drink due to the mixing of the citrus extract, , Health supplements and the like.
도 1은 본 발명의 실험예에 따른 항산화력 비교실험 결과 그래프,
도 2는 본 발명의 실험예에 따른 암세포주 성장억제 실험 결과 그래프,
도 3은 인체 유래 방광암 세포주 5637에 대한 항암성 실험 결과 그래프,
도 4는 인체 유래 방광암 세포주 5637에 대한 성장억제 정도를 MTT assay를 통하여 측정한 결과 그래프,
도 5는 마우스 대식세포주인 Raw 264.7 세포를 사용한 세포독성 실험결과 그래프.FIG. 1 is a graph showing the results of an antioxidant activity test according to Experimental Example of the present invention,
FIG. 2 is a graph showing an experiment result of cancer cell growth inhibition according to the experimental example of the present invention,
FIG. 3 is a graph showing an anticancer activity test result for a human-derived bladder
FIG. 4 is a graph showing the degree of growth inhibition of bladder
FIG. 5 is a graph showing cytotoxicity test results using Raw 264.7 cells, a mouse macrophage cell line.
이하에서는 본 발명의 바람직한 실시예를 상세하게 설명한다. 본 발명을 설명함에 있어서 관련된 공지 기술에 대한 구체적인 설명이 본 발명의 요지를 흐리게 할 수 있다고 판단되는 경우 그 상세한 설명을 생략하기로 한다. 명세서 전체에서, 어떤 부분이 어떤 구성요소를 "포함"한다고 할 때, 이는 특별히 반대되는 기재가 없는 한, 다른 구성요소를 제외하는 것이 아니라 다른 구성요소를 더 포함할 수 있음을 의미한다.Hereinafter, preferred embodiments of the present invention will be described in detail. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, exemplary embodiments of the present invention will be described in detail with reference to the accompanying drawings. Throughout the specification, when an element is referred to as "including " an element, it means that it can include other elements, not excluding other elements, unless specifically stated otherwise.
본 발명자들은 기존의 쿰부차가 낮은 항산화 활성을 가지며, 특유의 신맛을 가짐에 따라 음용하기 어렵다는 문제가 있음에 주목하고, 이는 해결하기 위하여 예의 노력을 한 결과, 콤부차에 녹차와 감귤 추출액을 혼합하는 경우 항상화확성이 높아지고 음용역시 쉬워지는 것을 확인하고 본 발명에 이르게 되었다.The inventors of the present invention have noted that there is a problem that existing Kombucha has low antioxidative activity and that it is difficult to drink because it has a unique sour taste. As a result of intensive efforts to solve this problem, It has always been found that the coenzyme is increased and the consumption is also easy, leading to the present invention.
따라서 본 발명은 (a) 콤부차 균주를 홍차와 혼합한 다음 1차 배양하여 콤부차 배양액을 수득한 다음, 배양액과 세균막(Pellicle)을 분리하는 단계; (b) 녹차 추출액 및 감귤 추출액을 준비하는 단계; 및 (c) 상기 콤부차 배양액, 새균막, 녹차 추출액 및 감귤 추출액을 혼합한 다음, 2차 배양하여 콤부차를 수득하는 단계를 포함하는 감귤 및 녹차 추출액을 이용한 콤부차 제조방법에 관한 것이다.Accordingly, the present invention relates to a method for producing a microbial cell culture, which comprises (a) mixing a microbial strain with a black tea, followed by primary culture to obtain a comb secondary culture, and then separating the culture medium and a pellicle; (b) preparing green tea extract and citrus extract; And (c) culturing the comb secondary culture, fresh membrane, green tea extract, citrus extract, and secondary culturing to obtain comb secondary cells.
본 발명에 있어서 상기 녹차 추출액은 설탕을 추가로 포함하는 것을 특징으로 할 수 있다. 기존의 콤부차의 경우 특유의 신맛을 가지고 있으며, 홍차 발효물의 특성상 음용하는 것이 쉽지 않다 따라서, 신맛을 억제하기 위하여 당성분을 추가하는 것이 바람직하며, 쉽게 구할 수 있는 설탕을 첨가하는 것이 더욱 바람직하다. 이때 설탕의 사용량은 녹차 추출액 1L에 대하여 50~150g의 비율로 촘가하는 것이 바람직하며, 더욱 바람직하게는 녹차 추출액 1L에 대하여 80~110g을 첨가할 수 있다. In the present invention, the green tea extract may further include sugar. In the case of the conventional kombucha, it has a peculiar sour taste, and it is not easy to drink because of the characteristics of the fermented tea. Therefore, it is preferable to add sugar components to suppress sour taste, and it is more preferable to add easily obtainable sugar . In this case, the amount of sugar used is preferably 50 to 150 g per 1 L of the green tea extract, more preferably 80 to 110 g per 1 L of the green tea extract.
본 발명에 있어서, 상기 콤부차 추출액은 아세트산을 추가로 포함하는 것을 특징으로 할 수 있다. 콤부차 추출액은 신맛이 강하기는 하지만, 녹차 및 감귤추출물을 혼합하여 신맛이 줄어 들었으며, 이에 따라 변질될 수 있다. 따라서, 아세트산 성분을 추가하여 맛을 일정하게 유지하며, 보존기간을 늘리는 것이 더욱 바람직하다. 이때 첨가되는 아세트산의 양은 콤부차 추출액 1L에 대하여 100~1500㎕의 비율인 것이 바람직하며, 더욱 바람직하게는 콤부차 추출액 1L에 대하여 400~600㎕의 비율일 수 있다.In the present invention, the comb supplement extract may further include acetic acid. Although the sourness of the Sukbuka extract is strong, the sour taste is reduced by mixing the green tea and the citrus extract, and it can be altered accordingly. Therefore, it is more preferable to add an acetic acid component to keep the taste constant and increase the storage period. At this time, the amount of acetic acid to be added is preferably in the range of 100 to 1500 쨉 l per 1 L of the supernatant extract, more preferably 400 to 600 쨉 l per 1 L of the supernatant extract.
본 발명에 있어서, 상기 녹차 추출액은 녹차 1~5g을 100~500mL의 증류수에 90~120℃의 온도로 1~30분간 추출한 것을 특징으로 할 수 있으며, 상기 감귤 추출액은 감귤피 1~30g을 100~500mL의 증류수에 90~120℃의 온도로 1~30분간 추출한 것을 특징으로 할 수 있다. 녹차 및 감귤 추출액은 콤부차의 신맛의 정도 사용목적에 따라 원하는 방법으로 제조 가능하지만, 상기의 방법으로 추출하는 것이 바람직하다.In the present invention, the green tea extract may be prepared by extracting 1 to 5 g of green tea with 100 to 500 ml of distilled water at a temperature of 90 to 120 ° C for 1 to 30 minutes. The citrus extract may contain 1 to 30 g of citrus peel as 100 To 500 ml of distilled water at a temperature of 90 to 120 ° C for 1 to 30 minutes. The green tea and citrus extract can be prepared by a desired method depending on the purpose of use of the sour taste of kombucha, but it is preferable to carry out the extraction by the above method.
본 발명에 있어서, 상기 (c)단계는 콤부차 배양액 50~200mL, 세균막 1-~50g, 녹차 추출액 500~1200mL 및 감귤 추출액 100~300mL를 혼합하여 10~40℃에서 5~20일간 배양하는 것을 특징으로 할 수 있다.In the present invention, the step (c) may be carried out by mixing 50-200 mL of the comb culture medium, 1-50 g of the bacterial membrane, 500-100 mL of the green tea extract, and 100-300 mL of the citrus extract and incubating the mixture at 10 to 40 ° C for 5 to 20 days .
또한 본 발명은 제1항 내지 제6항 중 어느 한 가지 방법으로 제조되는 콤부차에 관한 것이다.
The present invention also relates to a comb secondary manufactured by any one of the methods of claims 1 to 6.
이하, 본 발명에 따른 구체적인 실시예를 들어 설명한다.
Hereinafter, a specific embodiment of the present invention will be described.
시료처리Sample Processing
일반 콤부차(K)와 감귤/녹차 콤부차(CK)는 원심분리 후 상등액을 사용하였고, 세포실험에는 상등액을 주사기용 필터 유닛(pore size 0.45 μm, EMD Millipore Inc. Billerica, MA, USA)을 이용하여 여과한 후 RPMI-1640(Sigma-Aldrich Co., Saint Louis, MO, USA)에 희석하여 사용하였다. 감귤피 추출액은 감귤피 10 g에 200 mL 증류수를 첨가하는 비율로 10분간 열탕 추출하였다. 녹차 추출액은 녹차 티백(1.5 g, 설록원, Jeju, Korea) 한 개에 300 mL의 증류수를 첨가하는 비율로 10분간 열탕 추출하였다. 각 시료는 세포 성장 억제에 필요한 만큼 필터 유닛(0.45 μm, EMD Millipore Inc.)으로 여과하여 사용하였다.The supernatant was used as a supernatant after centrifugation. The supernatant was filtered through a syringe filter unit (pore size 0.45 μm, EMD Millipore Inc. Billerica, MA, USA) And then diluted with RPMI-1640 (Sigma-Aldrich Co., St. Louis, Mo., USA). Citrus bloom extract was extracted with 10 g of hot water for 10 minutes at a rate of adding 200 mL of distilled water to 10 g of citrus pear. The green tea extract was extracted with hot water for 10 minutes at a rate of 300 mL of distilled water added to one tea tea bag (1.5 g, Jeju, Korea). Each sample was filtered by filter unit (0.45 μm, EMD Millipore Inc.) as necessary to inhibit cell growth.
본 실험에서 사용한 콤부차는 local domestic Kombucha이며, 민간에서 분양하여 판매하는 것을 인터넷으로 구매하여 사용하였다(www.auction,co.kr).
In this experiment, Kombucha is a local domestic Kombucha, which is sold in the private sector and sold through the Internet (www.auction, com).
통계처리Statistical processing
본 실험은 독립적으로 3번 이상 반복실험을 실시하였다. 실험 결과는 통계분석용 프로그램 SPSS Version 18.0 Package Program(IBM, New York, NY, USA)을 이용하여 각 실험군의 평균과 표준편차를 계산하고 t-test분석, ANOVA분석 후 P<0.05 수준에서 Duncan's multiple range test를 이용하여 처리군 간의 유의성을 검증하였다.
This experiment was repeated three times or more independently. The results were analyzed by t-test and ANOVA analysis using the SPSS Version 18.0 Package Program (IBM, New York, NY, USA) for statistical analysis. Duncan's multiple range test to verify the significance between the treatment groups.
실시예Example 1 One
전배양을 통해 얻은 콤부차 배양액 100 mL에 녹차 추출액 700 mL, pellicle 20 g, 감귤피(남해상사, Jeju, Korea) 추출액 200 mL에 acetic acid 500 μL를 첨가하여 30℃조건으로 10일간 배양하였다.
To 100 mL of the supernatant obtained from the pre-culture, 500 μL of acetic acid was added to 700 mL of green tea extract, 20 g of pellicle, 200 mL of citrus pine (Jeju, Korea) and incubated at 30 ° C for 10 days.
비교예Comparative Example 1 One
콤부차는 녹차(동서녹차 티백, Seoul, Korea) 추출액 900 mL에 설탕 90 g을 교반한 후 전배양을 통해 얻은 배양액 100 mL과 pellicle 20 g을 넣어 30℃조건으로 10일간 배양(비교예 1)하였다.
100 g of the culture obtained from the pre-cultivation and 20 g of the pellicle were added to 900 mL of the extract (900 mL) of the green tea (East Green tea tea, Seoul, Korea) and incubated at 30 ° C for 10 days (Comparative Example 1) Respectively.
실험예1Experimental Example 1 : 세포배양 : Cell culture
실험에서 사용한 B16F10 마우스 피부악성종양 세포주, 5637 인간 방광암 세포주와 마우스 대식세포인 Raw 264.7 세포주는 한국 세포주 은행(KCLB, Seoul, Korea)에서 구입하여 RPMI-1640 (Sigma-Aldrich Co.)배지에 10% FBS(Gibco Inc. San Francisco, CA, USA)와 1% Penicillin(Gibco Inc.)을 넣고, 37℃, 5% CO2 조건에서 배양하였다.
The B16F10 mouse skin malignant tumor cell line, 5637 human bladder cancer cell line and mouse macrophage Raw 264.7 cell line used in the experiment were purchased from Korean Cell Line Bank (KCLB, Seoul, Korea) and cultured in RPMI-1640 (Sigma-Aldrich Co.) FBS (Gibco Inc. San Francisco, CA, USA) and 1% Penicillin (Gibco Inc.) were added and cultured at 37 ° C and 5% CO 2.
실험예Experimental Example 2 : 2 : ORACORAC assayassay
비교예 1의 일반 콤부차와 실시예 1의 감귤/녹차 콤부차의 ORAC value는 Ou 등(14)의 방법을 응용하여 비교 측정하였다. 본 실험에서 사용한 시료와 표준물질 및 시약은 75 mM phosphate buffer(pH 7.4)용액에 희석하여 사용하였다. AAPH(150 mM)는 실험 직전에 37℃ 에서 15분간 incubation한 뒤, 96-well plate에 100배로 희석된 시료 25 μμL와 fluorescein(40 nM) 120 μμL를 혼합하고 측정 시 AAPH(150 mM) 25 μμL를 첨가하였다. 측정은 fluorescence microplate reader(Spectra Max i3, Molecular Devices, Sunnyvale, CA, USA)를 이용하여 37℃ 에서 excitation은 485 nm, emission은 520 nm에서 2분 간격으로 총 1시간 동안 측정하였다. 측정값은 각 시료의 area under curve(AUC)를 구한 후 trolox의 표준곡선에 대입하여 나타내었다.The ORAC value of the common comb secondary of Comparative Example 1 and the citrus / green tea comb secondary of Example 1 were compared by the method of Ou et al. (14). The samples, reference materials and reagents used in this experiment were diluted in 75 mM phosphate buffer (pH 7.4). AAPH (150 mM) was incubated at 37 ° C for 15 minutes immediately before the experiment. Then, 25 μL of the diluted sample and 120 μL of fluorescein (40 nM) were mixed in a 96-well plate and AAPH (150 mM) Was added. The excitation was measured at 485 nm and the emission was measured at 520 nm for 2 minutes at 37 ° C for 1 hour using a fluorescence microplate reader (Spectra Max i3, Molecular Devices, Sunnyvale, CA, USA). The measured values were obtained by substituting the area under curve (AUC) of each sample into the standard curve of trolox.
비교예 1의 콤부차(K)와 실시예 1의 감귤 및 녹차의 추출액을 첨가한 콤부차(CK)의 항산화력을 비교하였다. 각 시료의 항산화력은 oxygen radical absorbance capacity(ORAC)를 측정하여 비교하였으며, 그 결과는 도 1과 같다. 앞선 연구들에 의하면, 콤부차는 높은 항산화력으로 인하여 활성산소로부터 세포를 보호하는 기능이 뛰어나다고 알려져 있다. Bhattacharya 등(12)은 당뇨 모델 생쥐를 이용한 실험에서 콤부차를 먹인 후 항산화력을 측정하였는데, 발효시키지 않은 차를 먹인 대조군에 비해 콤부차를 먹인 생쥐의 간세포 내 glutathione 감소를 현저하게 억제하였음을 보고한 바 있다. 본 연구에서 제조된 감귤/녹차 추출액 함유 콤부차의 경우는 일반 발효 콤부차의 항 산화력과 비교할 때 약 3배가량 증가하는 것으로 나타났으며, 이 항산화력의 증가는 녹차 및 감귤피 내에 강력한 항산화 물질이 존재함을 나타낸다고 할 수 있다. 실제로 감귤피 및 녹차의 항산화력 증진 효과는 많은 기존 연구들에서도 보고된 바 있다(15-17).
The antioxidative capacity of comb (carboxy) (K) of Comparative Example 1 and Comb (carboxy) supplemented with the extract of citrus and green tea of Example 1 were compared. The antioxidative capacity of each sample was compared by measuring the oxygen radical absorbance capacity (ORAC), and the results are shown in FIG. Previous studies have shown that combobacillus is superior in protecting cells against free radicals due to its high antioxidant capacity. Bhattacharya et al. (12) measured the antioxidant capacity after combing the mice in a diabetic model mouse. The results showed that the inhibition of glutathione in hepatocytes was significantly inhibited in the mice fed the unfermented tea There is one. The antioxidative capacity of the common fumaric acid was about 3 times higher than that of the common fumaric acid. The increase of the antioxidant activity of the fumaric acid contained in the citrus / Is present. In fact, the antioxidative effects of citrus peel and green tea have been reported in many previous studies (15-17).
실험예Experimental Example 3 : 세포 독성 실험( 3: Cytotoxicity experiment ( MTTMTT assayassay ))
실시예1의 감귤/녹차 콤부차(CK)처리에 따른 B16F10 피부암 세포주, 5637 인간 방광암세포주와 Raw 264.7 마우스 대식세포의 증식 억제 정도를 측정하기 위해 96-well plate에 각 세포주를 3x103/well로 분주하여 배양한 후 CK의 농도를 달리하여 24시간 배양하였다. 그 후 5 μg/mL MTT(Thiazolyl blue tetrazolium bromide)(Sigma Aldrich Co.) 시약을 10 μL씩 처리하여 1시간 반응시키고 배지를 제거한 후 DMSO를 100 μL씩 분주하여 생성된 formazan을 모두 녹인 후 570 nm에서 흡광도를 측정하였다. 세포의 증식률은 시료의 흡광도를 대조군(무처리군)의 흡광도에 대한 백분율로 나타내었다. In order to measure the degree of inhibition of proliferation of B16F10 skin cancer cell line, 5637 human bladder cancer cell line and Raw 264.7 mouse macrophage cell according to the citrus / green tea comb (CK) treatment of Example 1, each cell line was divided into 3x103 cells / well in a 96- And cultured for 24 hours at different concentrations of CK. Then, 10 μL of 5 μg / mL MTT (Thiazolyl blue tetrazolium bromide) (Sigma Aldrich Co.) reagent was added to each well, and the mixture was reacted for 1 hour. After removing the medium, 100 μL of DMSO was added to each well. The absorbance was measured. The proliferation rate of the cells was expressed as a percentage of the absorbance of the control (untreated group).
먼저, 실시예 1의 감귤피와 녹차 추출액을 함유한 콤부차의 항산화력이 비교예 1의 일반 콤부차에 비해 월등히 높아진 결과를 기초로 하여 각 성분의 항암성을 측정하였다. 녹차 추출액, 감귤피 추출액, 그리고 그 혼합액의 암세포주 성장 억제 정도를 MTT assay를 통하여 측정하였다. 각 시료는 0~20 μL/mL 의 농도로 24시간동안 처리하였고, 도 2와 같이 무첨가 군에 대한 백분율로 나타내었다. MTT assay의 결과를 보면, 감귤피 추출물에 비해 녹차 추출물의 항암효과가 상대적으로 높았으며, 각 성분의 단일 처리군 보다는 혼합액의 처리군에서 월등히 높은 항암성을 나타내었다. 특히 감귤/녹차 혼합액은 20 uL/ml의 농도에서 80% 이상의 피부악성종양 세포주의 성장을 억제하는 것으로 나타났다. 이는 각 추출물의 단일 효과와 비교할 때 현저한 상승효과를 나타낸 것으로, 각 성분은 서로 다른 기작으로 암세포의 성장을 저해하고 있음을 알 수 있다 First, the anticancer activity of each component was measured on the basis of the result that the antioxidative power of the kombucha containing the citrus peel and the green tea extract of Example 1 was much higher than that of the common comb negative of Comparative Example 1. Green tea extract, citrus bloom extract, and mixture thereof were measured by MTT assay. Each sample was treated for 24 hours at a concentration of 0 to 20 μL / mL and expressed as a percentage of the no-added group as shown in FIG. MTT assay showed that the anticancer effect of green tea extract was higher than that of Tangerine bark extract and showed much higher anticancer activity than the single treatment group of each component. In particular, the citrus / green tea mixture inhibited the growth of more than 80% of skin malignant tumor cell lines at a concentration of 20 uL / ml. This shows a remarkable synergistic effect when compared with the single effect of each extract. It can be seen that each component inhibits the growth of cancer cells by different mechanisms
인체 유래 방광암 세포주인 5637에 대한 항암성도 함께 측정이 되었으며, 그 결과는 도 3과 같다. 5637 방광암 세포주에 대한 항암성은 귤피 추출액 보다 녹차 추출액에서 강하게 나타났으며, 혼합액의 항암성은 녹차 추출액의 항암성과 비슷하게 나타났다. 이 결과를 토대로 보면, 방광암에 대한 항암성은 주로 녹차 성분에 의해 나타난다고 볼 수 있다. 방광암 세포주에 대한 결과에서도 약 20 μL/mL의 농도에서 60% 이상의 세포가 사멸되었으며, 세포의 50% 사멸을 나타내는 IC50는 10~20 μL/mL 농도 사이에 존재함을 알 수 있다. 앞선 피부암세포에 대한 결과와 비교할 때 5637 인간 방광암 세포주에서는 상승효과가 나타나지 않은 것으로 볼 때 추출물의 작용 기작은 5637 방광암 세포와 B16F10 피부암세포에 서로 다르다는 것을 추론할 수 있다.
The anticancer activity against the human bladder
실험예Experimental Example
4 : 인간 방광암 세포주 5637에 대한 CK의 항암성 실험 4: Anticancer effect of CK on human bladder
CK의 발효에 사용되는 성분 중 감귤피 추출액와 녹차 추줄액 각각의 항암성 측정 결과를 토대로 두 성분을 함유한 콤부차(실시예 1)를 10일간 배양하였다. 이 후 배양액을 45 μm필터로 제균 한 후, 방광암 세포주에 대한 성장 억제 정도를 MTT assay를 통하여 측정하였다. 그 결과는 도 4와 같았다. CK는 K와 비교하여 유의적으로 5637 방광암 세포주에 대해 높은 항암 활성을 나타내었고, 농도 의존적인 항암 활성을 나타내었다. 그러나 흥미롭게도, IC50값은 단일 성분들의 항암성 측정값과 비교할 때 증가한 것으로 나타났다. 이는 발효 과정 중에 단일 성분들의 파괴가 진행된 것으로 생각되며, 실제로 녹차 성분 중 강한 항암활성을 나타낸다고 알려진 EGCG의 생리적 활용도(bio-availability)가 시간에 따라 감소한다는 보고를 통해서도 추론 할 수 있다(18). 녹차와 감귤의 기능성분이 일반 콤부차로 이행되어 증진된 생리활성 음료를 개발 할 수 있을 것으로 생각하였고, 차후 각 성분의 화학적 안정성을 확보할 수 있는 연구가 진행되어야 할 것으로 생각이 된다.
Based on the results of the anticancer activity measurement of each of the citrus extract and green tea extract of the components used for the fermentation of CK, Combaux containing two components (Example 1) was cultured for 10 days. After this, the culture solution was sterilized with a 45 μm filter, and the degree of growth inhibition of the bladder cancer cell line was measured by MTT assay. The result was as shown in Fig. CK showed a higher anticancer activity against 5637 bladder cancer cell lines than K, and showed a dose - dependent anticancer activity. Interestingly, however, the IC50 value was increased when compared to anticancer measurements of single components. This may be due to the fact that the bioavailability of EGCG, which is known to exhibit strong anticancer activity among green tea components, decreases with time (18). It is believed that the functional ingredient of green tea and citrus can be developed into a generic chewing gum, which can promote the development of physiologically active beverages, and further studies should be conducted to ensure the chemical stability of each ingredient.
실험예Experimental Example 5 : 인간 5: Human 신장유래Kidney origin 유사 정상세포에 대한 독성 Toxicity to pseudo-normal cells
암세포에 대한 성장 억제 결과를 기초하여, 본 암세포 성장 저해능이 일반 세포 독성에 기인한 것이 아닌지를 살펴보기 위해 비사멸화(immortalization)된 마우스 대식세포주인 Raw 264.7 세포를 사용하여 세포독성을 확인하였고 그 결과는 도 5와 같았다. K 혹은 CK는 Raw 264.7 세포에 대하여 전체적으로 낮은 세포 독성을 나타내었고, CK는 K에 비해 오히려 세포 독성이 낮게 나타났다. 방광암 및 피부암 세포주와 다르게 Raw 264.7 세포는 100 μL/ml의 농도에서도 세포 독성이 현저하게 낮았다. 이상의 실험 결과로 볼 때, 감귤과 녹차의 추출액을 첨가하여 발효시킨 콤부차는 항암성이 일반 콤부차에 비해 높게 나타났으며, 녹차와 감귤피의 추출액이 상승효과(synergistic effect)를 나타내는 것으로 확인되었고, 마우스 대식세포를 이용한 독성실험에서 나타난 결과로 볼 때, 일반 세포에 대한 독성은 낮을 것으로 판단되었다. 이상의 결과를 토대로 우리는 녹차와 감귤피 추출액의 항산화 효과를 비롯한 생리활성 기능이 또한 미생물 발효 기능성 음료의 산업화를 위해서 확보되어야 할 중요한 사항 중 한 가지는 일반 세포에 대한 독성여부이며, Raw 264.7 대식세포를 사용하여 일반 세포 독성을 확인한 사례(19)에 기초하여 본 연구에서도 마우스 대식세포인 Raw 264.7 세포를 이용하여 일반 세포에 대한 독성의 정도를 조사하였다. 그 결과 CK는 암세포에 적용된 농도의 약 2배에서도 세포 독성이 크지 않았다. 더 많은 실험 데이터가 확보되어야 하겠지만, 본 연구의 결과로 비추어 볼 때 CK는 항암 기능성 음료로 개발될 수 있는 가능성을 나타냈다고 볼 수 있다. Based on the inhibition of growth of cancer cells, cytotoxicity was confirmed using Raw 264.7 cells, an immortalized mouse macrophage cell line, to examine whether the growth inhibition of cancer cells was caused by general cytotoxicity. The results were as shown in Fig. K or CK showed low overall cytotoxicity against Raw 264.7 cells and CK had lower cytotoxicity than K. Unlike bladder cancer and skin cancer cell lines, Raw 264.7 cells were significantly less cytotoxic at 100 μL / ml. From the above results, it was confirmed that the anticancer activity of the kombucha fermented with the citrus and green tea extracts was higher than that of the common combus subspecies, and the synergistic effect of the green tea extract and the citrus pus extract was confirmed , Toxicity test using mouse macrophages showed that toxicity to normal cells would be low. Based on the above results, one of the important points to be secured for the industrialization of microbial fermentation functional beverage, including the antioxidant effect of green tea and citrus extract, is toxicity to general cells, and Raw 264.7 macrophages In this study, the degree of toxicity to normal cells was also examined using Raw 264.7 cells, a mouse macrophage, on the basis of a general cytotoxicity assay (19). As a result, CK was not cytotoxic even at about twice the concentration applied to cancer cells. Although more experimental data should be obtained, the results of this study suggest that CK could be developed as an anti-cancer functional beverage.
이상으로 본 발명의 바람직한 실시예를 상세하게 설명하였다. 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다.The preferred embodiments of the present invention have been described in detail above. It will be understood by those of ordinary skill in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
따라서, 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허청구범위에 의하여 나타내어지며, 특허청구범위의 의미, 범위 및 그 균등 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.
Accordingly, the scope of the present invention is defined by the appended claims rather than the detailed description, and all changes or modifications derived from the meaning, range, and equivalence of the claims are included in the scope of the present invention Should be interpreted.
Claims (7)
(a) 콤부차 균주를 홍차와 혼합한 다음 1차 배양하여 콤부차 배양액을 수득한 다음, 배양액과 세균막(Pellicle)을 분리하는 단계;
(b) 녹차 추출액 및 감귤 추출액을 준비하는 단계; 및
(c) 상기 콤부차 배양액, 새균막, 녹차 추출액 및 감귤 추출액을 혼합한 다음, 2차 배양하여 콤부차를 수득하는 단계.
A method for manufacturing a comb secondary carcass using citrus fruits and green tea extracts comprising the steps of:
(a) a step of mixing a subspecies of Pseudomonas aeruginosa with a black tea, followed by primary culturing to obtain a comb secondary culture, and then separating the culture medium and a pellicle;
(b) preparing green tea extract and citrus extract; And
(c) mixing the comb culture supernatant, a fresh membrane, a green tea extract, and a citrus extract, and then secondary culturing to obtain comb secondary cells.
상기 녹차 추출액은 설탕을 추가로 포함하는 것을 특징으로 하는 콤부차 제조방법.
The method according to claim 1,
Wherein the green tea extract further comprises sugar.
상기 콤부차 추출액은 아세트산을 추가로 포함하는 것을 특징으로 하는 콤부차 제조방법
The method according to claim 1,
Characterized in that the comb secondary extract further comprises acetic acid.
상기 녹차 추출액은 녹차 1~5g을 100~500mL의 증류수에 90~120℃의 온도로 1~30분간 추출한 것을 특징으로 하는 콤부차 제조방법.
The method according to claim 1,
Wherein the green tea extract is prepared by extracting 1 to 5 g of green tea with 100 to 500 mL of distilled water at a temperature of 90 to 120 ° C for 1 to 30 minutes.
상기 감귤 추출액은 감귤피 1~30g을 100~500mL의 증류수에 90~120℃의 온도로 1~30분간 추출한 것을 특징으로 하는 콤부차 제조방법.
The method according to claim 1,
Wherein the citrus extract is prepared by extracting 1 to 30 g of citrus peel into 100 to 500 mL of distilled water at a temperature of 90 to 120 ° C for 1 to 30 minutes.
상기 (c)단계는 콤부차 배양액 50~200mL, 세균막 1-~50g, 녹차 추출액 500~1200mL 및 감귤 추출액 100~300mL를 혼합하여 10~40℃에서 5~20일간 배양하는 것을 특징으로 하는 콤부차 제조방법.
The method according to claim 1,
Wherein the step (c) comprises culturing the cells at 10 to 40 ° C for 5 to 20 days by mixing 50 to 200 ml of a comb culture medium, 1- to 50 g of a bacterial membrane, 500 to 1200 ml of a green tea extract, and 100 to 300 ml of a citrus extract, Gt;
6. A comb-bicycle produced by any one of claims 1-6.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160112720A KR101870522B1 (en) | 2016-09-01 | 2016-09-01 | Method of Manufacturing Kombucha with Extracts Using Green Tea and Citrus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160112720A KR101870522B1 (en) | 2016-09-01 | 2016-09-01 | Method of Manufacturing Kombucha with Extracts Using Green Tea and Citrus |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180026021A true KR20180026021A (en) | 2018-03-12 |
KR101870522B1 KR101870522B1 (en) | 2018-06-26 |
Family
ID=61728979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160112720A KR101870522B1 (en) | 2016-09-01 | 2016-09-01 | Method of Manufacturing Kombucha with Extracts Using Green Tea and Citrus |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101870522B1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108823260A (en) * | 2018-07-09 | 2018-11-16 | 常熟理工学院 | Fermented tea mycoderm and its preparation method and application |
CN109468341A (en) * | 2018-10-07 | 2019-03-15 | 南宁润生堂生物科技有限公司 | A kind of production method of fermented tea mycoderm zymolyte |
CN110786402A (en) * | 2019-12-09 | 2020-02-14 | 贵州省黎平县蝉之声农业发展有限公司 | Preparation method of orange black tea |
KR20200066842A (en) | 2018-12-03 | 2020-06-11 | 롯데칠성음료주식회사 | A kombucha composition and a prepartion method thereof |
KR20200094392A (en) * | 2019-01-30 | 2020-08-07 | 강산농원영농조합법인 | Method for producing Kombucha using Camellia sinensis and Petasites japonicus and Kombucha produced by the same method |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102308755B1 (en) | 2018-10-02 | 2021-10-06 | 서울대학교산학협력단 | Making method of low calorie kombucha using fermentated sugar |
KR102478724B1 (en) | 2020-01-31 | 2022-12-16 | 제주대학교 산학협력단 | A composition for diabetes or cardiovascular disease treatment comprising a citrus fermented kombucha |
KR102459439B1 (en) | 2020-05-22 | 2022-10-27 | 대구대학교 산학협력단 | Method for production of the fermented tea using lotus root and the fermented tea thereof |
KR20220073321A (en) | 2020-11-26 | 2022-06-03 | 정연미 | Method for producing kombucha comprising actinidia arguta |
KR102598663B1 (en) | 2021-02-05 | 2023-11-06 | 농업회사법인 대본주식회사 | Method of manufacturing ginger kombucha |
KR102484575B1 (en) | 2021-09-15 | 2023-01-05 | 주식회사 투페이지코리아 | Preparing Method of Kombucha beverages |
KR102405006B1 (en) | 2021-12-29 | 2022-06-08 | 권호성 | Kombucha composition having diet function |
KR20230122692A (en) | 2022-02-15 | 2023-08-22 | 윤이수 | Manufacturing method kombucha enhanced palatability |
KR102573871B1 (en) | 2023-01-30 | 2023-09-01 | 주식회사 마일포스트 | Process for preparation of kombucha using hemp seeds |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040023982A (en) * | 2002-09-12 | 2004-03-20 | 학교법인 계명기독학원 | Method for production of Kombucha containg green-tea extract |
KR20150124258A (en) * | 2014-04-28 | 2015-11-05 | 나눔허브 주식회사 | Kombucha fermentated composition |
-
2016
- 2016-09-01 KR KR1020160112720A patent/KR101870522B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040023982A (en) * | 2002-09-12 | 2004-03-20 | 학교법인 계명기독학원 | Method for production of Kombucha containg green-tea extract |
KR20150124258A (en) * | 2014-04-28 | 2015-11-05 | 나눔허브 주식회사 | Kombucha fermentated composition |
Non-Patent Citations (2)
Title |
---|
김은영. 콤부차의 항산화 활성 및 생물학적 특성. 안동대학교 석사학위논문 (2003.08.)* * |
김청이. 감귤 콤부차 발효액의 인체 방광암세포에 대한 성장억제와 Apotosis에 미치는 영향. 제주대학교 석사학위논문 (2015.08.)* * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108823260A (en) * | 2018-07-09 | 2018-11-16 | 常熟理工学院 | Fermented tea mycoderm and its preparation method and application |
CN109468341A (en) * | 2018-10-07 | 2019-03-15 | 南宁润生堂生物科技有限公司 | A kind of production method of fermented tea mycoderm zymolyte |
KR20200066842A (en) | 2018-12-03 | 2020-06-11 | 롯데칠성음료주식회사 | A kombucha composition and a prepartion method thereof |
KR20200094392A (en) * | 2019-01-30 | 2020-08-07 | 강산농원영농조합법인 | Method for producing Kombucha using Camellia sinensis and Petasites japonicus and Kombucha produced by the same method |
CN110786402A (en) * | 2019-12-09 | 2020-02-14 | 贵州省黎平县蝉之声农业发展有限公司 | Preparation method of orange black tea |
Also Published As
Publication number | Publication date |
---|---|
KR101870522B1 (en) | 2018-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101870522B1 (en) | Method of Manufacturing Kombucha with Extracts Using Green Tea and Citrus | |
Smolskaitė et al. | Comprehensive evaluation of antioxidant and antimicrobial properties of different mushroom species | |
KR20090034241A (en) | A method for fermentation of natural plants and herbal medicines, a fermented product prepared therefrom and a paharmaceutical composition, a cosmetic compositon and a food composition comprising the product | |
Chen et al. | Tyrosinase inhibitory effect and antioxidative activities of fermented and ethanol extracts of Rhodiola rosea and Lonicera japonica | |
KR101806800B1 (en) | Complex natural preservative comprising scutellaria baicalensis extract and method manufacture the same | |
KR100844185B1 (en) | The manfacturing method of fermentation artemisia tea with lactic acid | |
Yapar et al. | Protective effect of kombucha mushroom (KM) tea on phenol-induced cytotoxicity in albino mice | |
de Oliveira et al. | Kombucha benefits, risks and regulatory frameworks: A review | |
KR20150081921A (en) | Manufacturing method for fermentained beverage fermented by using the extract of Zizyphus jujuba and Cervi Parvum Cornu | |
KR101531157B1 (en) | A composition containing cryptotanshinone as a active ingredient for the treatment of dental caries and peridontal disease | |
KR102298700B1 (en) | Facturing method of functional liquefied healthfoods using Gastroia elata Blume and Polygonum multiflorum Thunberg | |
Trivedi et al. | Production of a herbal wine from Aloe vera gel and evaluation of its effect against common food borne pathogens and probiotics | |
Park et al. | Antioxidant and anti-inflammatory activity and cytotoxicity of ethanol extracts from rhynchosia nulubilis cultivated with ganoderma lucidum mycelium | |
KR101918942B1 (en) | Fermented drink using glycine max (L.) merrill and herbal ingredients and manufacturing method thereof | |
Huang et al. | Pecan shell by-products—phenolic compound contents and antimicrobial properties. | |
Abd-El et al. | Antibacterial effect of green tea and pomegranate peel extracts on Streptococcus mutans of orthodontic treated patients | |
Ćilerdžić et al. | Do Ganoderma lucidum and Salvia officinalis extracts exhibit synergistic antioxidant and antineurodegenerative effects? | |
KR101422247B1 (en) | A fermentation method of function and taste enhanced melomel using schizandra chinensis and honey and melomel fermented by the same | |
KR100697655B1 (en) | Fermented guava composition safty-established by microbial fermentation | |
KR101609130B1 (en) | Fermented extract of gastrodia elata with excellant antioxident activity and taste, and manufacturing method thereof | |
KR102020822B1 (en) | Aronia extract with reduced astringency and manufacturing method of the same | |
KR101231589B1 (en) | Goatsbeard extract or its fraction having antiviral, antioxidative and antimicrobial effects | |
KR101650255B1 (en) | persimmon beverage product fortified polyphenol ingredient and preparation method thereof | |
KR20150131483A (en) | Method for producing Platycodon grandiflorus fermented broth with enhanced antioxidant activity and inhibition activity of alpha-glucosidase | |
KR20140076258A (en) | A health beverage using jujube |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |